Keto-pantoyllactone (KPL) is a synthetic compound that is an analog of pantothenic acid (vitamin B5). It is synthesized by a process that involves the oxidation of pantothenic acid to form pantoyllactone, followed by the removal of the carboxyl group from the pantoyllactone molecule. KPL is a potent inhibitor of the enzyme pantothenate kinase, which is responsible for the phosphorylation of pantothenic acid. This inhibition of pantothenate kinase leads to a depletion of Coenzyme A (CoA), which is essential for many metabolic processes. As a result, KPL has been shown to have a variety of biological effects, including inhibition of cell growth, induction of apoptosis, and modulation of immune responses. It is being studied as a potential treatment for various diseases, including cancer, inflammatory diseases, and infectious diseases. The study of KPL is important because it can help to understand the role of pantothenate kinase in cellular metabolism and to develop new therapies for a variety of diseases.'
| ID Source | ID |
|---|---|
| PubMed CID | 39 |
| CHEBI ID | 18395 |
| SCHEMBL ID | 538500 |
| MeSH ID | M0051913 |
| Synonym |
|---|
| 4,4-dimethyldihydro-2,3-furandione |
| 4,4-dimethyl-tetrahydro-furan-2,3-dione |
| 4,4-dimethyl-4,5-dihydrofuran-2,3-dione |
| CHEBI:18395 |
| 2-oxopantoyl lactone |
| C01125 |
| dihydro-4,4-dimethyl-2,3-furandione |
| 13031-04-4 |
| 2-dehydropantolactone |
| 2-dehydropantoyl lactone |
| inchi=1/c6h8o3/c1-6(2)3-9-5(8)4(6)7/h3h2,1-2h3 |
| hrtoqfbqofifee-uhfffaoysa- |
| dihydro-4,4-dimethyl-2,3-furandione, 97% |
| 4,4-dimethyloxolane-2,3-dione |
| 4,5-dihydro-4,4-dimethyl-2,3-furandione; dihydro-4,4'-dimethyl-2,3-furandione; ketopantolactone; tetrahydro-4,4-dimethyl-2,3-furandione; alpha-ketopantolactone;4,4-dimethyldihydrofuran-2,3-dione |
| A806062 |
| 2,3-furandione, dihydro-4,4-dimethyl- |
| einecs 235-891-7 |
| ketopantoyl lactone |
| ketopantolactone |
| keto-pantoyllactone |
| dihydro-4,4-dimethylfuran-2,3-dione |
| FT-0636778 |
| 4,4-dimethyldihydrofuran-2,3-dione |
| AKOS015905266 |
| 2-oxo-3,3-dimethyl-gamma-butyrolactone |
| SCHEMBL538500 |
| 4,4-dimethyldihydro-2,3-furandione # |
| DTXSID30156448 |
| J-005785 |
| mfcd00012331 |
| DS-15458 |
| Q27103050 |
| AMY24290 |
| LCZC2502 |
| C72205 |
| SY251591 |
| CS-0065829 |
| EN300-116454 |
| Class | Description |
|---|---|
| tetrahydrofurandione | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Pathway | Proteins | Compounds |
|---|---|---|
| phosphopantothenate biosynthesis II | 0 | 11 |
| phosphopantothenate biosynthesis II | 0 | 12 |
| Pantothenate and coenzyme A biosynthesis III | 1 | 19 |
| Pantothenate biosynthesis III | 1 | 7 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 2 (20.00) | 18.7374 |
| 1990's | 1 (10.00) | 18.2507 |
| 2000's | 2 (20.00) | 29.6817 |
| 2010's | 4 (40.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 10 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||